Promising Growth and Investment in the Cell Therapy Industry during the First Quarter of 2012

In the first quarter of 2012, publicly traded companies in the cell-based therapy industry continued to show promising overall growth. Highlights included $85 million in new capital investment and steady clinical trial progress. Click here to download the full report Erik Miljan believes that the actual value is several fold higher, find out more at our 3 day Stem Cells …

The move from big pharma to stem cells is underway as Shire makes a $200M deal to purchase Pervasis

FierceBiotech recently reported that Shire is buying the biotech Pervasis Therapeutics with an eye toward boosting its regenerative medicine unit, adding the small company’s cellular therapy in mid-stage development for vascular repair in patients on hemodialysis. The buyout follows Shire’s purchase of Advanced BioHealing last year in a deal that created the business that specializes in cell-based therapies. Ireland-based Shire …